knowing01

Register for our webinar on Tuesday, 19 November 2024, at 5pm CET / 11am EST to learn how Multiomics AI will shape the future of research and development! In the rapidly evolving field of research and development (R&D), staying ahead with traditional approaches is not enough. Multiomics AI is reshaping the landscape by integrating diverse biological data - genomics, proteomics, metabolomics, etc. - into a unified framework that provides deeper insights into complex biological systems, transforming our understanding of disease mechanisms and accelerating therapeutic innovation. At knowing01, our software solution uses Multiomics AI to optimize research processes and enable complex data analyses. Want to learn more? Then join our webinar: 🗓 When? Tuesday, 19 November 2024 ⏰ Time? 5:00 pm CET / 11:00 am EST (just 15 minutes!) 💻 Where? Online Dr. Nikola Müller, CEO & Founder of knowing01, and Karolina Worf, Online Content Manager at knowing01, will talk about "The future of R&D: How Multiomics AI will shape research in 2025 and beyond". 👉 More information and registration: https://lnkd.in/dkazCXRx #WomenInIT #Webinar #Research #R&D #PrecisionMedicine #Multiomics #knowing01 #Innovation #Future #FemaleLeaders #DrugDiscovery #DiseaseMechanism #DataScience #DataIntegration #DataAnalysis #Biotechnology #Biotech #ArtificialIntelligence #AI

A new study in Cell uses AI to unlock the hidden world of RNA viruses in diverse ecosystems, highlighting the untapped diversity of the global RNA virosphere. Current metagenomic tools often struggle to identify RNA viruses with highly divergent sequences. Therefore, Xin Hou et al. developed LucaProt, an advanced deep learning model capable of identifying highly divergent RNA-dependent RNA polymerase (RdRP) sequences, even those often missed by standard metagenomic tools. Applied to over 10,000 metatranscriptomes from diverse environments, this approach identified 161,979 potential RNA virus species and 180 RNA virus supergroups, expanding our view of RNA virus complexity like never before. Key highlights: ➡ Unprecedented diversity: LucaProt has discovered tens of thousands of new RNA virus species, including RNA viruses with genomes up to 47,250 nucleotides in length. ➡ Ubiquitous presence: New RNA viruses have been found everywhere - from the air to hot springs to hydrothermal vents - demonstrating the resilience and adaptability of RNA viruses in extreme environments. ➡ Technological advance: LucaProt combines sequence and structural data, setting a new standard for the detection and documentation of RNA viruses. This study not only advances RNA virus discovery, but also provides a computational tool for researchers to further explore this vast virosphere and highlights the complex roles that RNA viruses can play in different ecosystems. Read the full article by Xin Hou et al. published in Cell on 09 October 2024 here: https://lnkd.in/dqbiZsTW #WeeklyPublication #VirusDiscovery #Virology #RNAviruses #Research #Metagenomics #ML #MachineLearning #LucaProt #Innovation #Genomics #DeepLearning #Cell #Biotech #ArtificialIntelligence #AIinScience #AI

🌟 We are thrilled to be featured in the latest “Bavarian Biotech News” by BioM! Proud to be listed alongside groundbreaking Bavarian biotech innovators. This recognition highlights our journey from winning the m4 Award to securing new pre-seed funding. A big thank you to the BioM Biotech Cluster Development GmbH for supporting start-ups like ours as we work together to advance life sciences! ➡ Read the full story in the “Bavarian Biotech News” on page 10 or here: https://lnkd.in/dzNJKQJp #BavarianBiotechs #BioM #Biotech #Funding #Innovation #knowing01 #LifeSciences #News #Startups

🚀 The future of research and development is here - are you ready? Then join our webinar on Tuesday, November 19, 2024, at 5pm CET / 11am EST! 2025 will be a transformational year for research, with Multiomics AI leading the charge. Imagine integrating genomics, proteomics, metabolomics and more in a powerful framework - gaining deeper insights into disease mechanisms and revolutionizing therapeutic discovery. This is not just a glimpse into the future, it's happening now. At knowing01, our easy-to-use Multiomics AI platform is designed to optimize research and make complex biological data analysis faster and easier than ever before. Curious how this can accelerate your work? Don't miss our upcoming webinar where we dive into the future of research and development (R&D): 🗓 When? Tuesday, 19 November 2024 ⏰ Time? 5:00 pm CET / 11:00 am EST (just 15 minutes!) 💻 Where? Online Join Dr. Nikola Müller, CEO & Founder of knowing01, and Karolina Worf, Online Content Manager at knowing01, as they explore "The future of R&D - How Multiomics AI will shape research in 2025 and beyond". 👉 Ready to innovate? Register now: https://lnkd.in/dkazCXRx #WomenInIT #Webinar #Research #R&D #PrecisionMedicine #Multiomics #knowing01 #Innovation #Future #FemaleLeaders #DrugDiscovery #DiseaseMechanism #DataScience #DataIntegration #DataAnalysis #Biotechnology #Biotech #ArtificialIntelligence #AI

Groundbreaking news in regenerative medicine! A new study in Nature shows the world's first successful cure of type 1 diabetes through a transplant of reprogrammed stem cells. This treatment enabled a 25-year-old woman to produce her own insulin for over a year, eliminating the need for insulin injections. Led by researchers at Peking University, the team converted the patient's cells into insulin-producing islet cells and transplanted them into the patient's abdominal muscles. This innovation allows for monitoring via MRI and offers a new solution for type 1 diabetes patients worldwide, especially since the availability of donors for traditional islet transplants is limited. Key highlights: ➡ Patient independence: The woman has been insulin-free for over a year and has stable blood sugar levels. ➡ Innovative techniques: Researchers used chemically induced pluripotent stem cells, a refined approach from the original Yamanaka method. ➡ Long-term impact: This success opens the door to larger trials and could pave the way for a scalable treatment, potentially eliminating the need for immunosuppressants in future protocols. The potential to revolutionize diabetes care and restore insulin independence is immense. Read the full news article by Smriti Mallapaty, published in Nature on 26 September 2024, here: https://lnkd.in/gNU955DE #WeeklyPublication #Type1Diabetes #T1D #StemCellTherapy #StemCellTransplant #StemCells #Research #RegenerativeMedicine #Nature #MedicalInnovation #Insulin #Innovation #DiabetesCure #Diabetes

Honoring Women in Biotech: Today we honor Anna Wessels Williams (1863 - 1954), a pioneering American pathologist whose contributions shaped modern public health practices and vaccine development. Anna W. Williams broke new ground in medical research and diagnostics and initiated significant advances in combating some of the most devastating diseases of her time. 🔬 Pioneering work to combat diphtheria Williams made a major breakthrough when she isolated a strain of the diphtheria bacillus that played a crucial role in making diphtheria antitoxin available and cost effective. Her work contributed directly to the fight against diphtheria, one of the greatest health threats of the early 20th century. 🩺 Diagnostic innovations for many diseases Throughout her career, Williams worked on vaccines, treatments and diagnostic tests for diseases such as rabies, meningitis and influenza, ensuring more accurate and faster detection of infections - a cornerstone of modern healthcare. ⭐ Public health leadership In 1932, Williams became the first woman elected chair of the American Public Health Association's laboratory section, solidifying her legacy as a leader in both science and public health. Her leadership reflected her lifelong commitment to advancing laboratory science as an important tool in the fight against infectious diseases. Follow us on LinkedIn to learn more about brilliant women in science like Anna W. Williams! #WomenInScience #WomenInBiotech #VaccineDevelopment #STEM #Rabies #PublicHealth #Pioneer #Pathology #Meningitis #Legacy #Inspiration #Influenza #Healthcare #DiphtheriaAntitoxin #Diphtheria #Diagnostics #Bacteriologist #AnnaWesselsWilliams

Attending BIO-Europe 2024 in Stockholm from 4-6 November? Don't miss the chance to get in touch with our visionary CEO and Founder Dr Nikola Müller. At knowing01 GmbH, we are on a mission to transform how life science data is used in research. Based in Munich and founded in 2020, we are committed to helping researchers in industry and academia unlock the full potential of their data. Our software solution links complex biomedical datasets to deliver actionable insights and filters out noise to reveal what matters. Curious to learn how our software solution can accelerate your discoveries and maximize the value of your data? Join us at BIO-Europe 2024 from 4-6 November 2024 in Stockholm, Sweden, and have a one-on-one conversation with Dr Nikola Müller. This is a great opportunity to learn more about how we can make a difference together. Secure your meeting with Nikola via the BIO-Europe partneringONE system. Register here: https://bit.ly/4biIK0G Alternatively, you can also contact us directly: https://lnkd.in/edhAhvpZ We look forward to meeting you in Stockholm! #AI #BIOEurope #Biotech #Biotechnology #Connect #DataAnalytics #DataScience #DiseaseResearch #EBDGroup #FemaleLeaders #Innovation #knowing01 #KnowledgeGraphs #Multiomics #Omics #Partnering #Research #StartUp #Stockholm #Sweden #WomenInIT

New bioRxiv preprint uncovers the metabolic landscape of human solute carrier transporters, providing fresh insights into cellular metabolism and function. Despite the critical role of human solute carrier (SLC) transporters in regulating the exchange of chemicals across cell membranes, a systematic understanding of their individual functions has been lacking. In this comprehensive study, Wiedmer et al. mapped the metabolite and transcriptional profiles of various SLCs, revealing new details about their functional roles. Key highlights: ➡ Metabolite fingerprinting: Using targeted metabolomics, the study profiled 189 intracellular metabolites and identified putative substrates or metabolic pathway connections for 71 SLCs that had not previously been known to have substrates, including SLC45A4 as a new polyamine transporter. ➡ Functional gene groups: By linking transcriptional and metabolic data, the team discovered functionally related SLC groups and shed light on their roles in osmolyte balancing and glycosylation. ➡ Further implications: This mapping provides a valuable resource for future studies of gene function and offers a blueprint for further research into human metabolism and cellular identity. View the full study by Wiedmer et al., published 24 September 2024 in bioRxiv, here: https://lnkd.in/dH6ueWZw #WeeklyPublication #Transporters #Transcriptomics #SoluteCarrier #SLCTransporters #SLC45A4 #SLC #Preprint #Multiomics #Metabolomics #MembraneTransporter #FunctionalGenomics #CellularMetabolism #bioRxiv

One week ago, our CEO and founder, Dr. Nikola Müller, returned from yet another inspiring BioTechX Europe in Basel!🇨🇭It was an incredible experience centered around the latest innovations in biotech and pharma, where technology meets healthcare to drive transformative change. What was special about this year's congress? Here are some impressions: 1. New technologies lead the way: AI, LLMs, and knowledge graphs are undeniably at the forefront. From data management to advanced analytics, these tools continue to reshape Biotech. However, much of their potential is still being explored and refined through use cases. 2. Innovation at work: There is a strong drive for new solutions, but many have yet to prove their business value. Whether it is integrating AI into clinical research or using knowledge graphs for data insights, the industry recognizes that making a transformative impact takes time and thorough implementation. 3. Journey of integration: The congress highlighted the challenges and opportunities of integrating these technologies. It's clear that realizing their full potential requires a thoughtful approach and patience as we all navigate the complex path from idea to tangible results. Nikola Müller, CEO and founder of knowing01, attended BioTechX Europe 2023 at Basel, Switzerland. She enjoyed engaging in meaningful discussions, sharing insights, and connecting with fellow innovators who are equally passionate about the future of biotech. Thanks to everyone who stopped by at our startup booth! If you missed BioTechX 2024 or didn't get a chance to meet Nikola, let's get in touch and explore how we can help you make groundbreaking discoveries: https://lnkd.in/edhAhvpZ #AI #Basel #Biotech #Biotechnology #BiotechStartups #BioTechX #DataIntegration #DiseaseResearch #FutureOfHealthcare #HealthcareTransformation #Innovation #knowing01 #KnowledgeGraphs #LifeSciences #LLM #Multiomics #Networking #Omics #ResearchAndDevelopment #Startup #WomenInTech

A new Cancer Cell study reflects on a decade of single-cell RNA-sequencing in cancer research and offers groundbreaking insights into tumor biology, shaping the future of cancer diagnosis and treatment! In this latest publication, Itay Tirosh and Mario L. Suva address the incredible complexity of cancer cell states, revealing how single-cell RNA-sequencing (scRNA-seq) has transformed our understanding of expression intra-tumor heterogeneity (eITH). They explore the most common cancer cell programs, from cell cycle and stress responses to EMT-like plasticity, and highlight how these distinct states drive tumor progression and therapy resistance. Key highlights: ➡ Definition of cancer cell states: The study demonstrates advanced computational approaches to characterize different malignant cell states, uncovering recurring gene expression patterns across different cancer types. ➡ Expression intra-tumor heterogeneity (eITH): The article discusses the complexity in defining and naming eITH, addressing challenges such as cancer cell plasticity and the coexistence of multiple expression programs within single tumors. ➡ Future directions: As scRNA-seq technologies continue to develop, they envision broader clinical applications and an exciting shift towards spatial transcriptomics and Multiomic profiling to better capture the tumor microenvironment. Read the full article by Itay Tirosh and Mario L. Suva, published in Cancer Cell on 9 September 2024, to learn more about this decade-long journey: https://lnkd.in/dzArknGV #WeeklyPublication #TumorMicroenvironment #TumorBiology #SingleCell #scRNAseq #PrecisionOncology #Multiomics #IntraTumorHeterogeneity #Heterogeneity #GeneticHeterogeneity #Genetics #GeneExpression #eITH #CancerResearch #CancerCell